In addition, agonistic anti-TIM-1 monoclonal antibody or other ligands can enhance the function of T cells [39, 82], increase CD8+ T cells and NK cells, reduce MDSC in tumor tissues, and inhibit tumor growth (data not shown). This evidence concerns the gene CD8A and neoplasm.